About Genhouse

With passion in research, with wisdom for humanity
About Genhouse

Genhouse Bio, headquartered in Suzhou Industrial Park, a vibrant hub of culture and innovation, is dedicated to the discovery and development of globally advanced, targeted oncology therapeutics. The core management team brings together extensive expertise in corporate management, novel drug R&D, and clinical development. The Company pioneered the drug discovery philosophy of "Biology-Driven Smart Design." Guided by this principle, it has established four proprietary and sustainable integrated technology platforms: Structural Biology, Drug Discovery and Design, Druggability Evaluation, and Translational Medicine. Leveraging a modular and streamlined R&D system, it focuses its efforts on the Ras-MAPK signaling pathway and synthetic lethality. Through these efforts, it has advanced a robust pipeline with multiple candidates at the clinical and pre-clinical stages that hold global competitive advantages. Its goal is to provide internationally competitive solutions for the precision and combination therapy of tumours.

  • Efficient full-process R&D system
    Guided by the philosophy of “Biology-Driven Smart Design”, the Company has established integrated technology platforms led by structural biology,and constructed a full-process R&D system spanning from target validation to clinical development, enabling efficient and collaborative advancement from Hit → Lead → PCC to pre-clinical and clinical development. Meanwhile, the Company continues to explore the empowering application of artificial intelligence throughout the entire innovative drug R&a
  • Sustainable in-house innovation capacity
    The core competitiveness of Genhouse derives from its sustainable in-house innovation capacity. The company deeply integrates structural biology, computational chemistry and artificial intelligence to provide a robust systematic foundation for the sustained advancement of its pipeline. With a strategic focus on the Ras-MAPK signaling pathways and synthetic lethality, the Company has established a portfolio comprising seven self-developed drug candidates, four of which are in clinical stages. The
  • Global collaboration and value creation
    Genhouse has completed several material overseas collaboration and licensing deals: For GH31 (a MAT2A inhibitor), the Company entered into a global collaboration with Gilead Sciences, with an upfront payment of US$80 million and total deal value up to US$1.5 billion. For GH21 (an SHP2 inhibitor), the Company out-licensed the ex-China rights to HUYABIO International, with total deal value up to US$282 million. Meanwhile, the Company has established strategic collaborations with multiple top-tier

Kuifeng Wang

the Founder, Chairman and CEO

CEO Remarks

At Genhouse, we dedicate ourselves to the advancement of both the quality and length of patients' lives. Starting with "undruggable targets", we have built an innovative pipeline with differentiated advantages and global value. Over a decade of R&D, we have established distinctive integrated technology platforms that make innovation streamlined and modular, significantly accelerating the R&D process. We attract like-minded talent united by a patient-centered mission, and continuously strengthen our capacity in in-house innovation and internationalization. Today, Genhouse is home not only to world-class scientists, but also to a community of biopharmaceutical professionals driven by vision and commitment. We remain dedicated to delivering more and better treatments to patients worldwide.

History
Financing
  • 2026
    Crossover financing was completed
    Summitted A1 to the HKEX
  • 2025
    Converted to a joint stock company
  • 2024
    B2 Financing was completed
  • 2023
    B1 Financing was completed
  • 2022
    B Financing was completed
  • 2021
    A Financing was completed
  • 2020
    Pre-A Financing was completed
  • 2018
    Angel Financing was completed
Pipeline Development
  • 2026
    Obtained IND approval of GH21 in combination with GH55 in China
    Obtained IND approval of GH31 in China
    MAT2A inhibitor GH31 entered global collaboration with Gilead
  • 2025
    Obtained IND approval of GH31 in the U.S.
    Obtained IND approvals of GH56 in both China and the U.S.
  • 2024
    Obtained IND approvals of GH2616 in both China and the U.S.
    Obtained IND approval of GH21 in combination with Garsorasib in China
    Entered into two combination therapy collaborations with AstraZeneca and Zhengda Tianqing
  • 2023
    Obtained IND approval of GH21 in combination with Osimertinib in China
  • 2022
    Obtained IND approvals of GH55 in both China and the U.S.
  • 2021
    Obtained IND approval of GH21 in China. HUYABIO International obtained IND approval of GH21 in the U.S.
  • 2020
    SHP2 inhibitor GH21 was licensed out to HUYABIO International
  • 2017
    Obtained National High-Tech Enterprise Certificate
  • 2014
    Founded in Suzhou
Privacy Statement

Genhouse Bio (Suzhou) Ltd. (“Genhouse” or “We”) respects the privacy of visitors (“Users”) to our website www.genhousebio.com (“Site”), so we have developed this website privacy statement (“Privacy Statement”). This Privacy Statement indicates what information we collect about you and how that information is used. We may update the content of the Privacy Statement and suggest reading it regularly when you visit our Site.

Personal Information Collected by Genhouse

When you visit the Site, usually we will not collect any personal information from you. We might track your DNS and analyze the data to obtain understanding on visit trends. However, your identity will always remain anonymous, unless you specifically and knowingly provide it to us. When you provide such information, we will collect your personal information, such as when you contact us through the phone number or email address posted on the Site. But no matter when and how we collect your personal information, we will always provide link to this Privacy Statement. By willingly providing your personal information to us, you make the consent that we could use the information collected according to this Privacy Statement and admit that the information will be transferred from your locale to our office or server.

Information Disclosures and Sharing

Except as provided below, we will not share or sell your Personal Information with third parties unless otherwise stated by this Privacy Statement.

We might share your information according to this Privacy Statement, with Related Party who have consented to follow this Privacy Statement. Your personal information might also be transferred to other Related Party who represents us for purpose stated when we collect those information or other purposes permitted by law, such as Site evaluation, data management or technical support.

We might sell or buy business or assets during our operation. If Genhouse is acquired, merged, reorganized or dissolved or other alike situations happened, personal information might be part of the assets transferred. We may share personal information to respond to duly authorized subpoenas or other lawful information requests of governmental authorities, including to meet national security or law enforcement requirements, to provide Internet security, or where required by law.

Cookies

We might put a digital tag (more precisely “cookies”) on your hard disk driver for the server to recognize your computer and track usage information. Cookies will not reveal your personal information and you could always stay anonymous to us. The information we collected from Cookies will only be used for internal purpose and improve the service we provided to you through the Site. Users of our Site always have the option of disabling cookies via their browser preferences. If under any circumstances we collected your personal information, we will always inform you with your planned usage, contact and any Third Party that might get this information. All your personal information will maintain secrecy.

Links to Other Websites

If you apply to a job through our Site, you might be directed to other websites operated by Third Party. This Privacy Statement does not extend to any of these websites. Genhouse will not be responsible for any personal information collected by these websites operated by Third Party. Therefore, for any cases that a Third Party collect or use your personal information, Genhouse will not be legally responsible. We advise you to contact those websites directly and get their policies on personal information collection, safety, sharing and disclosure.

Contact Information

If you have any questions about our Privacy Statement, please do not hesitate to contact us at [infor@genhousebio.com].

Effective and Last Updated: April 15th 2021